Document Detail


Investigational agents against platinum-resistant ovarian cancer.
MedLine Citation:
PMID:  17302527     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ovarian cancer is still the fourth cause of death by cancer among women and is the most fatal among gynaecological tumours. The goal of treatment for patients with recurrent, platinum-resistant (platinum-free interval < 6 months) ovarian cancer is the palliation of symptoms because no evidence indicates that present therapies may prolong survival in this setting of patients. Successful management of these patients depends on the identification of agents that are not cross-resistant with platinum compounds. The development of molecular biology is providing us with new information on the molecular basis of cancer, its mechanism of initiation and progression, and supply the need of a more patient-tailored therapy where specific tumours are treated with specific drugs. This paper reports and discusses new developments in the treatment of platinum-resistant ovarian cancer patients. The authors present proteomic advances, including the HER kinases, the 26S proteasome and the angiogenesis pathway. The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next 10 years promise to be filled with therapeutic advances for patients with ovarian cancer.
Authors:
Domenica Lorusso; Gabriella Ferrandina; Francesco Fanfani; Maria Lucia Gagliardi; Giovanni Scambia
Related Documents :
16857247 - Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizin...
17617517 - Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
12538447 - Prevention of ovarian cancer: intraepithelial neoplasia.
15357517 - Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian...
19117447 - Profiling of endogenous serum phosphorylated peptides by titanium (iv) immobilized meso...
25347577 - Red cell distribution width and other red blood cell parameters in patients with cancer...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  16     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-16     Completed Date:  2007-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  325-36     Citation Subset:  IM    
Affiliation:
Catholic University of the Sacred Heart, Gynecologic Oncology Unit, Largo A Gemelli, 8 00168 Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm*
Female
Humans
Ovarian Neoplasms / drug therapy*
Platinum Compounds / therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Platinum Compounds

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The new paradigm in the treatment of colorectal cancer: are we hitting the right target?
Next Document:  Emerging drug therapies for preventing spontaneous preterm labor and preterm birth.